Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and Lamivudine

Islatravir (MK-8591) is a nucleoside reverse transcriptase translocation inhibitor in development for treatment and prevention of HIV-1. We present efficacy and safety data for islatravir and doravirine (DOR) through 96 weeks of the phase 2b trial (NCT03272347). METHODS: In this randomized, double-b...

Descripción completa

Detalles Bibliográficos
Autores principales: Molina, Jean-Michel, Yazdanpanah, Yazdan, Afani Saud, Alejandro, Bettacchi, Christopher, Chahin Anania, Carolina, Klopfer, Stephanie O., Grandhi, Anjana, Eves, Karen, Hepler, Deborah, Robertson, Michael N., Hwang, Carey, Hanna, George J., Correll, Todd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JAIDS Journal of Acquired Immune Deficiency Syndromes 2022
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377497/
https://www.ncbi.nlm.nih.gov/pubmed/35972855
http://dx.doi.org/10.1097/QAI.0000000000002879

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377497/
https://www.ncbi.nlm.nih.gov/pubmed/35972855
http://dx.doi.org/10.1097/QAI.0000000000002879

Ejemplares similares